We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer’s disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.
SchneiderLSMangialascheFAndreasenNFeldmanHGiacobiniEJonesRMantuaVMecocciPPaniLWinbladBKivipeltoM2014Clinical trials and late-stage drug development for Alzheimer’s disease: An appraisal from 1984 to 2014J Intern Med275251283
2.
LundkvistJHalldinMMSandinJNordvallGForsellPSvenssonSJanssonLJohanssonGWinbladBEkstrandJ2014The battle of Alzheimer’s Disease - the beginning of the future Unleashing the potential of academic discoveriesFront Pharmacol5102
3.
ZhangCDuvicM2006Treatment of cutaneous T-cell lymphoma with retinoidsDermatol Ther19264271
4.
CramerPECirritoJRWessonDWLeeCYKarloJCZinnAECasaliBTRestivoJLGoebelWDJamesMJBrundenKRWilsonDALandrethGE2012ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse modelsScience33515031506
5.
VeeraraghavaluKZhangCMillerSHefendehlJKRajapakshaTWUlrichJJuckerMHoltzmanDMTanziREVassarRSisodiaSS2013Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”Science340924f
6.
TesseurILoACRoberfroidADietvorstSVanBBBorgersMGijsenHMoecharsDMerckenMKempJD’HoogeRDeSB2013Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”Science340924e
7.
PriceARXuGSiemienskiZBSmithsonLABorcheltDRGoldeTEFelsensteinKM2013Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”Science340924d
8.
FitzNFCronicanAALefterovIKoldamovaR2013Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”Science340924c
9.
BalducciCPaladiniAMicottiETolomeoDLaVPGrigoliERichardsonJCForloniG2015The continuing failure of bexarotene in Alzheimer’s disease miceJ Alzheimers Dis46471482
10.
LambertJCHeathSEvenGCampionDSleegersKHiltunenMCombarrosOZelenikaDBullidoMJTavernierBLetenneurLBettensKBerrCPasquierFFievetNBarberger-GateauPEngelborghsSDeDPMateoIFranckAHelisalmiSPorcelliniEHanonOde PancorboMMLendonCDufouilCJaillardCLeveillardTAlvarezVBoscoPMancusoMPanzaFNacmiasBBossuPPiccardiPAnnoniGSeripaDGalimbertiDHannequinDLicastroFSoininenHRitchieKBlancheHDartiguesJFTzourioCGutIVanBCAlperovitchALathropMAmouyelP2009Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s diseaseNat Genet4110941099
11.
HaroldDAbrahamRHollingworthPSimsRGerrishAHamshereMLPahwaJSMoskvinaVDowzellKWilliamsAJonesNThomasCStrettonAMorganARLovestoneSPowellJProitsiPLuptonMKBrayneCRubinszteinDCGillMLawlorBLynchAMorganKBrownKSPassmorePACraigDMcGuinnessBToddSHolmesCMannDSmithADLoveSKehoePGHardyJMeadSFoxNRossorMCollingeJMaierWJessenFSchurmannBHeunRvan den BusscheHHeuserIKornhuberJWiltfangJDichgansMFrolichLHampelHHullMRujescuDGoateAMKauweJSCruchagaCNowotnyPMorrisJCMayoKSleegersKBettensKEngelborghsSDe DeynPPVanBCLivingstonGBassNJGurlingHMcQuillinAGwilliamRDeloukasPAl-ChalabiAShawCETsolakiMSingletonABGuerreiroRMuhleisenTWNothenMMMoebusSJockelKHKloppNWichmannHECarrasquilloMMPankratzVSYounkinSGHolmansPAO’DonovanMOwenMJWilliamsJ2009Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s diseaseNat Genet4110881093
12.
LazarANBichCPanchalMDesbenoitNPetitVWTouboulDDauphinotLMarquerCLaprevoteOBrunelleADuyckaertsC2013Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patientsActa Neuropathol125133144
13.
PierrotNTytecaDD’auriaLDewachterIGaillyPHendrickxATasiauxBHaylaniLEMulsNN’kuliFLaquerriereADemoulinJBCampionDBrionJPCourtoyPJKienlen-CampardPOctaveJN2013Amyloid precursor protein controls cholesterol turnover needed for neuronal activityEMBO Mol Med5608625
14.
KoldamovaRPLefterovIMIkonomovicMDSkokoJLefterovPIIsanskiBADeKoskySTLazoJS200322R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretionJ Biol Chem2781324413256
15.
FolsteinMFFolsteinSEMcHughPR1975Mini-mental state. A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res12189198
16.
VandenbergheRVanLKIvanoiuASalmonEBastinCTriauEHasselbalchSLawIAndersenAKornerAMinthonLGarrauxGNelissenNBormansGBuckleyCOweniusRThurfjellLFarrarGBrooksDJ201018F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trialAnn Neurol68319329
17.
IvanoiuADricotLGilisNGrandinCLhommelRQuenonLHanseeuwB2015Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for alzheimer’s disease with disease-related biomarkersJ Alzheimers Dis43835847
18.
SjogrenMVandersticheleHAgrenHZachrissonOEdsbaggeMWikkelsoCSkoogIWallinAWahlundLOMarcussonJNaggaKAndreasenNDavidssonPVanmechelenEBlennowK2001Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference valuesClin Chem4717761781
19.
JackCRJrAlbertMSKnopmanDSMcKhannGMSperlingRACarrilloMCThiesBPhelpsCH2011Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement7257262
20.
JansenWJOssenkoppeleRKnolDLTijmsBMScheltensPVerheyFRVisserPJAaltenPAarslandDAlcoleaDAlexanderMAlmdahlISArnoldSEBaldeirasIBarthelHvan BerckelBNBibeauKBlennowKBrooksDJvan BuchemMACamusVCavedoEChenKChetelatGCohenADDrzezgaAEngelborghsSFaganAMFladbyTFleisherASvan der FlierWMFordLForsterSForteaJFoskettNFrederiksenKSFreund-LeviYFrisoniGBFroelichLGabryelewiczTGillKDGkatzimaOGomez-TortosaEGordonMFGrimmerTHampelHHausnerLHellwigSHerukkaSKHildebrandtHIshiharaLIvanoiuAJagustWJJohannsenPKandimallaRKapakiEKlimkowicz-MrowiecAKlunkWEKohlerSKoglinNKornhuberJKrambergerMGVanLKLandauSMLeeDYdeLMLisettiVLleoAMadsenKMaierWMarcussonJMattssonNdeMAMeulenbroekOMeyerPTMintunMAMokVMolinuevoJLMollergardHMMorrisJCMroczkoBVan der MusseleSNaDLNewbergANordbergANordlundANovakGPParaskevasGPParnettiLPereraGPetersOPoppJPrabhakarSRabinoviciGDRamakersIHRamiLde ResendeOCRinneJORodrigueKMRodriguez-RodriguezERoeCMRotURoweCCRutherESabriOSanchez-JuanPSantanaISarazinMSchroderJSchutteCSeoSWSoeteweyFSoininenHSpiruLStruyfsHTeunissenCETsolakiMVandenbergheRVerbeekMMVillemagneVLVosSJvan Waalwijk van DoornLJWaldemarGWallinAWallinAKWiltfangJWolkDAZbochMZetterbergH2015Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysisJAMA31319241938
21.
LandauSMLuMJoshiADPontecorvoMMintunMATrojanowskiJQShawLMJagustWJ2013Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloidAnn Neurol74826836
22.
MuraTProust-LimaCJacqmin-GaddaHAkbaralyTNTouchonJDuboisBBerrC2014Measuring cognitive change in subjects with prodromal Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry85363370
23.
DumurgierJVercruysseOPaquetCBomboisSChauletCLaplancheJLPeoc’hKSchraenSPasquierFTouchonJHugonJLehmannSGabelleA2013Intersite variability of CSF Alzheimer’s disease biomarkers in clinical settingAlzheimers Dement9406413
